Karen I. Sweiss
Clinical Assistant Professor, Pharmacy Practice
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
Colloquium Lecture Series (PSCI 425), 8/26/2024 – 12/6/2024
Colloquium Lecture Series (PSCI 425), 8/26/2024 – 12/6/2024
Pathobiology of Cancer (PATH 511), 1/8/2024 – 4/26/2024
PDAT 9: Hematology/Oncology (PHAR 509), 1/8/2024 – 4/26/2024
PDAT 9: Hematology/Oncology (PHAR 509), 1/8/2024 – 4/26/2024
PDAT 9: Hematology/Oncology (PHAR 509), 1/8/2024 – 4/26/2024
PDAT 9: Hematology/Oncology (PHAR 509), 1/8/2024 – 4/26/2024
PDAT 9: Hematology/Oncology (PHAR 509), 1/8/2024 – 4/26/2024
PDAT 9: Hematology/Oncology (PHAR 509), 1/8/2024 – 4/26/2024
Selected Grants
MC-FludT19-PK: An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Underg, Medac GmbH., 2/9/2024 - 2/9/2029, Obligated Amount: $83791; Anticipated Amount: $83791
Heme-18: Minimal Residual Disease-Guided Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Multiple Myeloma Patients, Sanofi., 6/1/2023 - 11/30/2023, Obligated Amount: $2660818.02; No Anticipated Amount Set
"MC-FludT19-PK: An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation ", Medexus., 6/1/2023 - Present, No Obligated Amount Set; No Anticipated Amount Set
Expand Trial, Allogene., 5/1/2023 - Present, No Obligated Amount Set; No Anticipated Amount Set
Monumental-3, Janssen Biotech., 4/1/2023 - Present, No Obligated Amount Set; No Anticipated Amount Set
AB-205-301: A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 plus Standard of Care versus Placebo plus Standard of Care in, AB-205-301., 3/3/2023 - Present, No Obligated Amount Set; No Anticipated Amount Set
BMS CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM), BMS CA057-001., 3/1/2023 - Present, No Obligated Amount Set; No Anticipated Amount Set
BGB-11417-105: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB 11417 as Monotherapy, in Combination With Dexamethasone and, Beigene., 2/1/2023 - Present, No Obligated Amount Set; No Anticipated Amount Set
CTA: HEME-18 - Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma, Genzyme Corp., 8/23/2022 - 10/31/2026, Obligated Amount: $2660818.02; Anticipated Amount: $2660818.02
Selected Publications
Mohyuddin, Ghulam Rehman, Guadamuz, Jenny S, Ascha, Mustafa S, Chiu, Brian C-H, Patel, Pritesh R, Sweiss, Karen, Rohrer, Rebecca, Sborov, Douglas, Calip, Gregory S. (2024). Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study. Blood Advances, 8, (21), 5539-5541. doi:10.1182/bloodadvances.2024013600.
Nabulsi, Nadia A, Nazari, Jonathan L, Lee, Todd A, Patel, Pritesh R, Sweiss, Karen I, Le, Thy, Sharp, Lisa K. (2024). Perceptions of prescription opioids among marginalized patients with hematologic malignancies in the context of the opioid epidemic: a qualitative study. Journal of Cancer Survivorship, 18, (4), 1285-1296. doi:10.1007/s11764-023-01370-9.
Maahs, Lucas, Patel, Pritesh, Koshy, Matthew, Sweiss, Karen, Chen, Zhengjia, Xu, Ziqiao, Aydogan, Bulent, Rondelli, Damiano. (2024). High dose total marrow irradiation (TMI) does not increase long‐term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT). European Journal Of Haematology, 113, (1), 110-116. doi:10.1111/ejh.14195.
Mandava, Z, Hamilton, P, Patel, LK, Sharp, K, Sweiss, . (2024). CO154 Prevalence of Unmet Social Needs and Post-Transplant Outcomes Among Adult Sickle Cell Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Value in Health, 27, (6), s46. doi:10.1016/j.jval.2024.03.241.
Monteiro, Andrea L, Yousef, Andro, Sweiss, Karen, DiDomenico, Robert, Sharp, Lisa K. (2024). The role of shared decision-making in cancer pain management: Insights from a systematic review.. Journal of Clinical Oncology, 42, (16_suppl), e24078-e24078. doi:10.1200/jco.2024.42.16_suppl.e24078.
Rodriguez, Ana Avila, Hadidi, Danny, Hofmeister, Craig, Quigley, John, Zappia, Maria, Frolov, Maxim, Benevolenskaya, Elizaveta V, Sanchez, Matias, Kadkol, Shrihari, Sborov, Douglas, Rondelli, Damiano, Uzoka, Chukwuemeka, Sweiss, Karen. (2024). Minimal Residual Disease (MRD)-Driven Cessation of Maintenance: Free from Drug Therapy in Multiple Myeloma (FREEDMM trial in progress). Transplantation and Cellular Therapy, 30, (2), s393-s394. doi:10.1016/j.jtct.2023.12.552.
Maahs, Lucas, Koshy, Matthew, Sweiss, Karen, Ahn, Kang-hyun, Chen, Zhengjia, Uzoka, Chukwuemeka, Galvez, Carlos, Rubinstein, Paul, Quigley, John, Saraf, Santosh L, Rodriguez, Ana Avila, Aydogan, Bulent, Mahmud, Nadim, Rondelli, Damiano. (2024). Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial. Transplantation and Cellular Therapy, 30, (2), s162-s163. doi:10.1016/j.jtct.2023.12.207.
Sweiss, Karen, Hydren, Jay R, Martinez, Jorge Arturo Hurtado, Sborov, Douglas W, Patel, Pritesh Rajni, Sharp, Lisa, Ahlstrom, Jennifer M, Hofmeister, Craig. (2024). Cannabis and Cannabinoid Use and Perceptions in Patients with Plasma Cell Disorders: A National Healthtree Foundation for Multiple Myeloma Survey. Transplantation and Cellular Therapy, 30, (2), s146-s147. doi:10.1016/j.jtct.2024.01.046.
Sweiss, Karen, Kim, Kyeongmin, Guo, Janet, Hill, Kasey, Abbott, Nicole, Sanchez, Matias E, Uzoka, Chukwuemeka, Quigley, John, Rondelli, Damiano, Sborov, Douglas W, Harvey, R Donald, Nooka, Ajay K, Dhodapkar, Madhav Vishnu, Kaufman, Jonathan L, Joseph, Nisha, Lonial, Sagar, Patel, Pritesh Rajni, Phelps, Mitch A, Hofmeister, Craig. (2024). Mymel: A Phase 1 Trial of AUC-Targeted High Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Transplant. Transplantation and Cellular Therapy, 30, (2), s168-s169. doi:10.1016/j.jtct.2023.12.216.
Notable Honors
2020, 2020 Best Oral Abstract Award, BMT Pharmacist Conference at the 2020 Transplantation and Cellular Therapy (TCT) Conference
Selected Presentations
Sweiss, Karen. (2024 April 06). Updates and Challenges with BsAbs and CAR-T in Myeloma. Central Illinois Hematology Oncology Conference. Peoria, IL.
Sanchez, matias, Sweiss, Karen. (2024 January 31). Positioning the CART before the Horse: Sequencing of BsAbs and CAR-T. Multiple Myeloma Chicago Rounds.